There just seems to be traction in a lot of areas. The building blocks being put into place with the advisory board and recent expertise being hired, the drug moving forward with Cd12 as the virus gains unfortunate momentum in most countries, the failure of the first round of drugs to stem the tide, and insider investments being made showing the belief in the drug. So most of the short’s reasons are going away.